Pediatric IPEX-Associated Dermatitis Responds To Dupilumab: Evidence from Skin Transcriptomics and Immune Profiling

Area of Science:

• Immunology
• Dermatology
• Genetics

Background:

• Immunodysregulation, Polyendocrinopathy, Enteropathy, and X-linked (IPEX) syndrome is a rare, severe autoimmune disorder.
• FOXP3 gene mutations underlie IPEX, often leading to debilitating dermatitis, diabetes, and enteropathy.
• Conventional treatments for IPEX dermatitis, such as sirolimus, can be insufficient for severe cases.

Purpose of the Study:

• To evaluate the efficacy of Dupilumab, an anti-IL-4Rα monoclonal antibody, in treating severe, refractory dermatitis in an IPEX patient.
• To investigate the immunological mechanisms underlying Dupilumab's therapeutic effect in IPEX-associated dermatitis.

Main Methods:

• A clinical case study of a 2-year-old IPEX patient with refractory dermatitis was conducted.
• Whole-exome sequencing confirmed the FOXP3 mutation; skin biopsies and peripheral blood mononuclear cells (PBMCs) were analyzed.
• Treatment involved Dupilumab combined with sirolimus and prednisone, with clinical response assessed by the Eczema Area and Severity Index (EASI).

Main Results:

• Skin biopsies showed elevated IL-13 and upregulation of Th1/Th2 inflammatory genes.
• Dupilumab treatment led to significant clinical improvement, with EASI scores dropping from 24.8 to 0.4 over 8 months.
• Flow cytometry revealed reduced Th1/Th2 cells and increased regulatory T cells (Treg and Th3) with enhanced immunosuppressive markers.

Conclusions:

• Dupilumab demonstrates significant promise for managing refractory dermatitis in IPEX syndrome.
• The therapy effectively attenuates dual Th1/Th2 inflammation characteristic of IPEX dermatitis.
• Dupilumab promotes beneficial regulatory immune responses, highlighting its potential in treating complex autoimmune skin conditions.